Dr. Oskar Hansson has performed internationally recognized clinical and translational research focusing on the earliest phases of Alzheimer’s and Parkinson’s diseases.

His landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2006) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally. His work on biomarkers has led to over 350 original peer-reviewed publications.

Ten years ago, he started the prospective and longitudinal Swedish BioFINDER study where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders.